tiprankstipranks
Trending News
More News >
Skye Bioscience, Inc. (SKYE)
:SKYE
US Market
Advertisement

Skye Bioscience (SKYE) Earnings Dates, Call Summary & Reports

Compare
814 Followers

Earnings Data

Report Date
Nov 06, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.3
Last Year’s EPS
-0.1
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Skye Bioscience's progress. While the company showcased significant advancements in its clinical trials and financial stability, it also faced challenges with increased R&D expenses and a substantial net loss. The strategic developments and promising preclinical data are positive highlights, but the enrollment challenges in the extension study indicate areas needing attention.
Company Guidance
During Skye Bioscience's second quarter 2025 financial results and business update call, key guidance metrics included the advancement of the Phase IIa CBeyond program, which is progressing ahead of schedule with enrollment completed by February and the 26-week visit for the last patient anticipated soon. Approximately 50% of the original study's patients are eligible for the extension study, with optimism for high participation. The Data Safety Monitoring Committee has reviewed the study four times without recommending changes, underscoring effective management. Skye Bioscience anticipates reporting top-line results by late Q3 or early Q4. Financially, the company ended Q2 with $48.6 million in cash and equivalents, projecting their capital to fund operations through Q1 2027. Research and development expenses rose to $14.3 million due to contract manufacturing and clinical trial costs, while general and administrative expenses decreased slightly to $3.9 million. The company reported a net loss of $17.6 million. The upcoming months are critical, with several milestones such as a KOL event and top-line data release expected to shape the future development of nimacimab.
Phase IIa CBeyond Study Progress
The Phase IIa CBeyond study for nimacimab is advancing as planned, on budget, and ahead of schedule. Enrollment was completed in February, and the 26-week visit for the last patient is projected to occur very shortly. The Data Safety Monitoring Committee has reviewed the study four times with no recommendations for changes.
Promising Preclinical Data
The combination of nimacimab and a suboptimal tirzepatide dose demonstrated 44% vehicle-adjusted weight loss in a preclinical study. Nimacimab alone showed 21.5% weight loss, and it reduced rebound weight gain when used as a maintenance therapy post-incretin treatment.
Financial Stability
Skye ended the second quarter with $48.6 million in cash and cash equivalents, expecting to fund operations and key clinical milestones through at least Q1 2027. Research and development expenses increased, primarily due to contract manufacturing and clinical trial costs.
Strategic Developments and Hiring
Skye expanded its team to 20 employees, with key hires in regulatory affairs, quality, clinical operations, and CMC. The deliberate scaling aims to minimize downtime between clinical trials and support nimacimab's advancing development activities.

Skye Bioscience (SKYE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SKYE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 06, 2025
2025 (Q3)
-0.30 / -
-0.1
Aug 07, 2025
2025 (Q2)
-0.32 / -0.44
-0.2-120.00% (-0.24)
May 08, 2025
2025 (Q1)
-0.29 / -0.28
-0.18-55.56% (-0.10)
Mar 20, 2025
2024 (Q4)
-0.28 / -0.24
-0.3633.33% (+0.12)
Nov 07, 2024
2024 (Q3)
-0.25 / -0.10
-3.1796.85% (+3.07)
Aug 09, 2024
2024 (Q2)
-0.20 / -0.20
-0.875.00% (+0.60)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SKYE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 07, 2025
$3.55$3.52-0.85%
May 08, 2025
$1.79$1.81+1.12%
Mar 20, 2025
$1.89$2.25+19.05%
Nov 07, 2024
$5.44$5.71+4.96%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Skye Bioscience, Inc. (SKYE) report earnings?
Skye Bioscience, Inc. (SKYE) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
    What is Skye Bioscience, Inc. (SKYE) earnings time?
    Skye Bioscience, Inc. (SKYE) earnings time is at Nov 06, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SKYE EPS forecast?
          SKYE EPS forecast for the fiscal quarter 2025 (Q3) is -0.3.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis